抗 TNF-α 治疗贝赫切特综合征和结节病相关性难治性葡萄膜炎：单中心 131 例研究。
Anti-TNF-α Therapy for Refractory Uveitis Associated with Behçet's Syndrome and Sarcoidosis: A Single Center Study of 131 Patients.
机构信息
Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan.
出版信息
Ocul Immunol Inflamm. 2022 Jan 2;30(1):223-230. doi: 10.1080/09273948.2020.1791346. Epub 2020 Aug 20.
PURPOSE
The efficacy of infliximab (IFX) and adalimumab (ADA) for treating Behçet's syndrome (BS) and sarcoidosis has not been compared adequately.
METHODS
We reviewed the medical records of patients with uveitis diagnosed at Tokyo Medical University Hospital and compared the efficacy of IFX and ADA for BS and the efficacy of ADA for sarcoidosis and BS.
RESULTS
68 patients in IFX group and 63 patients in ADA group were analyzed. In BS patients, IFX and ADA were both effective in improving uveitic macular edema (UME). ADA improved UME in BS but not in sarcoidosis patients. The efficacy of ADA in reducing doses of corticosteroids and glaucoma medications was better in sarcoidosis than in the BS group.
CONCLUSION
Both IFX and ADA are efficacious in improving UME in BS patients. The reason that ADA improves UME better in BS than in sarcoidosis may be due to the difference in pathogenesis between these diseases.
目的
英夫利昔单抗（IFX）和阿达木单抗（ADA）治疗白塞病（BS）和结节病的疗效尚未得到充分比较。
方法
我们回顾了在东京医科大学医院诊断为葡萄膜炎的患者的病历，并比较了 IFX 和 ADA 治疗 BS 的疗效，以及 ADA 治疗结节病和 BS 的疗效。
结果
IFX 组 68 例，ADA 组 63 例。在 BS 患者中，IFX 和 ADA 均能有效改善葡萄膜炎性黄斑水肿（UME）。ADA 改善了 BS 患者的 UME，但未改善结节病患者的 UME。ADA 减少皮质类固醇和青光眼药物剂量的效果在结节病患者中优于 BS 组。
结论
IFX 和 ADA 均能有效改善 BS 患者的 UME。ADA 在 BS 中改善 UME 的效果优于结节病的原因可能是两种疾病的发病机制不同。
Zotero 插件